J2351 HCPCS code: Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq
J2351 is the HCPCS Level II code for injection, ocrelizumab, 1 mg and hyaluronidase-ocsq. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 920 per day on DME suppliers.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2025-04-01 |
| Last action effective | 2025-04-01 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| DME suppliers | 920 | Prescribing Information |
| outpatient hospital claims | 920 | Prescribing Information |
| practitioner claims | 920 | Prescribing Information |
What changed for J2351
- April 2025: Code appears in this HCPCS release
- 2025-04-01: J2351 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J2351?
J2351 is the HCPCS Level II code for injection, ocrelizumab, 1 mg and hyaluronidase-ocsq. Short descriptor: "Inj ocrelizumab 1mg hya-ocsq".
Does Medicare cover J2351?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J2351 can be billed per day?
920 on DME suppliers; 920 on outpatient hospital claims; 920 on practitioner claims (NCCI medically unlikely edits).
Related J23 codes
- J2300 — Injection, nalbuphine hydrochloride, per 10 mg
- J2305 — Injection, nitroglycerin, 5 mg
- J2310 — Injection, naloxone hydrochloride, per 1 mg
- J2311 — Injection, naloxone hydrochloride (zimhi), 1 mg
- J2312 — Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg
- J2313 — Injection, naloxone hydrochloride (zimhi), 0.01 mg
- J2315 — Injection, naltrexone, depot form, 1 mg
- J2320 — Injection, nandrolone decanoate, up to 50 mg
- J2323 — Injection, natalizumab, 1 mg
- J2325 — Injection, nesiritide, 0.1 mg
- J2326 — Injection, nusinersen, 0.1 mg
- J2327 — Injection, risankizumab-rzaa, intravenous, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J2351
- Watch J2351 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J2351
Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.